24 May 2013
Keywords: chimerix, gains, rights, gilead, cidofovir, licensed, fellow
Article | 22 September 2003
Chimerix has licensed rights from fellow US firm Gilead Sciences to develop oral derivatives of the latter's antiviral compound cidofovir,
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
22 September 2003
29 September 2003
23 May 2013
© 2013 thepharmaletter.com